Analysts at MLV & Co. cut their price objective on shares of Galena Biopharma (NASDAQ:GALE) from $6.00 to $5.00 in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports. MLV & Co.‘s target price indicates a potential upside of 71.23% from the stock’s previous close. Galena Biopharma Inc (NASDAQ:GALE) shares after opening at $2.40on last trade day and at the end of the day closed at $2.22. Company price to sales ratio in past twelve months was calculated as 94.74 and price to cash ratio as 4.96. Galena Biopharma Inc (NASDAQ:GALE)showed a negative weekly performance of -23.97%.
Zogenix, Inc. (NASDAQ:ZGNX) provides statement on Massachusetts denial of legitimate option for patients with severe chronic pain: Company statement:
“…We believe Governor Patrick’s ban on Zohydro ER only serves to unfairly restrict patient access to the only hydrocodone pain reliever available for long-term, daily, severe chronic pain patients who are obtaining relief with short-acting hydrocodone combination products, but who are at risk for potentially fatal liver toxicity due to their daily intake of acetaminophen. Ultimately, the ban on the prescription medication will add to patient suffering in the state…Contrary to some recent media reports, most other opioid medications on the market are both equal to or more potent than Zohydro ER (e.g., oxycodone, fentanyl, hydromorphone and oxymorphone), and all are available in higher strengths per unit-of-use than Zohydro ER. Claims that Zohydro ER is “more powerful” or “more addictive” than other commonly prescribed opioids are not supported by scientific data…The simple fact is that any medication, including opioid pain relievers, presents a danger to the person misusing or abusing it. That’s why Zogenix has taken extraordinary steps to support the appropriate use of Zohydro ER through a voluntary, comprehensive set of educational tools and safeguards to augment the FDA industry mandated class-wide Risk Evaluation Mitigation Strategy (:REMS) for extended-release opioids.” Zogenix, Inc. (NASDAQ:ZGNX) shares fell -6.83% in last trading session and ended the day on $2.73. ZGNX return on assets ratio is recorded as -105.40%. Zogenix, Inc. (NASDAQ:ZGNX) yearly performance is 51.67%.
TheStreet Quant Ratings rates IsoRay, Inc. (NYSEMKT:ISR) as a sell. The company’s weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and poor profit margins. IsoRay, Inc. (NYSEMKT:ISR) shares moved down -1.70% in last trading session and was closed at $2.31, while trading in range of $2.21 – $2.50. IsoRay, Inc. (NYSEMKT:ISR) year to date (YTD) performance is 362.00%.
TheStreet Ratings team rates Hanwha Solarone Co Ltd (NASDAQ:HSOL) as a Sell with a ratings score of D. Hanwha Solarone Co Ltd (NASDAQ:HSOL) weekly performance is -18.75%. On last trading day company shares ended up $2.86. Hanwha Solarone Co Ltd (NASDAQ:HSOL) distance from 50-day simple moving average (SMA50) is -6.52%. Analysts mean target price for the company is $5.00.
Leave a Reply